ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Deep Learning-Powered Nanoplasmonic Biosensing Approach Enables Ultrasensitive Extracellular Vesicles Profiling for Cancer Screening.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Strategies for Multiplexing Plasmonic Biosensing.Sensors (Basel, Switzerland) · 2026Review
- Article
- Exosome-Based Liquid Biopsy in Biliary Tract Cancer: Nanotechnology-Enabled Strategies and Future Perspectives.International journal of nanomedicine · 2026Review
- Deep Learning-Powered Nanoplasmonic Biosensing Approach Enables Ultrasensitive Extracellular Vesicles Profiling for Cancer Screening.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Nanoplasmonic metasurface technology, known for its high sensitivity, has garnered significant attention in the field of cancer detection. However, its potential is currently hindered by the inefficient data processing and analysis of conventional biosensing approaches. Herein, a biosensing strategy based on the Kolmogorov-Arnold network (KAN)-enabled metasurface chip (metaEVchip) for ultrasensitive small extracellular vesicles (sEV) analysis in serum is proposed. By analyzing full-spectrum data from 600 pancreatic ductal adenocarcinoma (PDAC) patients and 1200 controls via KAN-powered deep learning nanoplasmonic biosensing, the strategy achieves an exceptional area under the curve (AUC) of 0.99 in an external validation set, outperforming traditional methods. Further exploration of this enhanced performance reveals KAN's mechanism for the simultaneous capture of multi-dimensional spectral features, an advantage that enables efficient data processing and accuracy. This advancement significantly expands the applicability of nanoplasmonic metasurfaces in biosensing and establishes a new paradigm for cancer screening and improved clinical management of multiple malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.